1.1M XNAS Volume
XNAS 17 Apr, 2025 5:30 PM (EDT)
Evolus Inc Key Metrics
Select
All financials are in USD Million and price data in USD
VIEW MORE
Low Financial Strength
Expensive Valuation
Technically Neutral
Momentum Trap
These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks.
View Similar
Embed DVM
Check Before You Buy
VIEW FULL CHECKLISTMedium rank
9Positive11Negative
45.0% Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
Evolus Inc Stock Price Analysis
Day Price Range | 10.8 (LTP) 10.311 LowHigh |
Week Price Range | 10.8 (LTP) 9.411 LowHigh |
Month Price Range | 10.8 (LTP) 8.713.7 LowHigh |
52 Week Price Range | 10.8 (LTP) 8.717.8 LowHigh |
Evolus Inc Live Price Chart
Switch to TradingView
Fetching data ...
Revenue forecast
Miss
Evolus Inc's Revenue was lower than average estimate 2 times in past 3 years
EPS forecast
Current EPS
Avg. Estimate
Hit
EPS is expected to grow by 27.2% in FY25
Consensus Recommendation
7 ANALYST Recommendations
STRONG BUY
The consensus recommendation from 7 analysts for Evolus Inc is STRONG BUY
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Evolus Inc Stock Analysis
Evolus Inc stock analysis with key metrics, changes, and trends.
| Evolus Inc Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
|---|---|---|---|---|---|
| Annual Revenue | $266.27 M | 31.76% | positive |
| |
| Annual Net Profit | $50.42 M | 18.26% | positive |
| |
| Price to Earning Ratio | -13.61 | - | negative |
| |
| Stock Price | $10.79 | -6.42% | negative |
| |
| Quarterly Revenue | $78.95 M | 29.42% | positive |
| |
| Quarterly Net profit | $6.79 M | 42.6% | positive |
| |
| Debt to Equity Ratio | 23.54 | - | negative |
| |
| Mutual Fund Holding | 40.02 % | 1.52% | positive |
| |
| Promoter Share Holding | 4.75 % | 0.14% | positive |
| |
| Interest Coverage Ratio | -1.66 | - | negative |
| |
| Institutional Holding | 82.42 % | 0.47% | positive |
| |
Loading data..
Evolus Inc - Company Profile
What does Evolus Inc do?
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Evolus Inc Board of directors
All Gross Remunerations are in USD